参考文献

［1］陈竺 . 医学遗传学［M］. 3 版 . 北京：人民卫生出版社，2015：69-280.

［2］魏于全，赫捷 . 肿瘤学［M］. 2版 . 北京：人民卫生出版社，2015：44-59.

［3］MA X T，LIU Y，LIU Y L，et al. Pan-cancer genome and transcriptome analyses of 1 699 paediatric leukaemias and solid tumours［J］. Nature，2018，555（7696）：371-376.

［4］STONE W L，KLOPFENSTEIN K J，HAJIANPOUR M J，et al. Childhood cancers and systems medicine［J］. Front Biosci（Landmark Ed），2017，22（7）：1148-1161.

［5］WILLIAMS L A，RICHARDSON M，MARCOTTE E L，et al. Sex ratio among childhood cancers by single year of age［J］. Pediatr Blood Cancer，2019，66（6）：e27620.

［6］LANDIER W，ARMENIAN S，BHATIA S. Late effects of childhood cancer and its treatment［J］. Pediatr Clin North Am，2015，62（1）：275-300.

［7］KONSTANTINOUDIS G，KREIS C，AMMANN R A，et al. Spatial clustering of childhood cancers in Switzerland：a nationwide study［J］. Cancer Causes Control，2018，29（3）：353-362.

［8］MURPHY M F，BITHELL J F，STILLER C A，et al.Childhood and adult cancers：contrasts and commonalities［J］. Maturitas，2013，76（1）：95-98.

［9］吕敏，田国祥，郭晓娟，等 . TARGET数据库的介绍及数据提取［J］. 中国循证心血管医学杂志，2019，11（4）：387-390.

［10］GRÖBNER S N，WORST B C，WEISCHENFELDT J，et al. Author correction：the landscape of genomic alterations across childhood cancers［J］. Nature，2018，559（7714）：E10.

［11］ALLIS C D，JENUWEIN T. The molecular hallmarks of epigenetic control［J］. Nat Rev Genet，2016，17（8）：487-500.

［12］LAWRENCE M S，STOJANOV P，POLAK P，et al.Mutational heterogeneity in cancer and the search for new cancer-associated genes［J］. Nature，2013，499（7457）：214-218.

［13］ZIMMERMAN R，SCHIMMENTI L，SPECTOR L. A catalog of genetic syndromes in childhood cancer［J］.Pediatr Blood Cancer，2015，62（12）：2071-2075.

［14］URQUHART T，COLLIN J. Understanding the endocrinopathies associated with the treatment of childhood cancer：part 1［J］. Nurs Child Young People，2016，28（8）：37-44.

［15］ENGEL A，LAMM S H. Arsenic exposure and childhood cancer-a systematic review of the literature［J］. J Environ Health，2008，71（3）：12-16.

［16］YIU T T，LI W. Pediatric cancer epigenome and the influence of folate［J］. Epigenomics，2015，7（6）：961-973.

［17］SWEET-CORDERO E A，BIEGEL J A. The genomic landscape of pediatric cancers：implications for diagnosis and treatment［J］. Science，2019，363（6432）：1170-1175.

［18］WU D，LUO X，FEURSTEIN S，et al. How I curate：applying American society of hematology-clinical genome resource myeloid malignancy variant curation expert panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies［J］.Haematologica，2020，105（4）：870-887.

［19］MIRABELLO L，ZHU B，KOSTER R，et al. Frequency of pathogenic germline variants in cancer-susceptibility genes in patients with osteosarcoma［J］. JAMA Oncol，2020，6（5）：724-734.

［20］SYLVESTER D E，CHEN Y，JAMIESON R V，et al.Investigation of clinically relevant germline variants detected by next-generation sequencing in patients with childhood cancer：a review of the literature［J］. J Med Genet，2018，55（12）：785-793.

［21］ZHANG J H，WALSH M F，WU G，et al. Germline mutations in predisposition genes in pediatric cancer［J］.N Engl J Med，2015，373（24）：2336-2346.

［22］BARDAI A，OVERWATER E，AALFS C M. Germline mutations in predisposition genes in pediatric cancer［J］.N Engl J Med，2016，374（14）：1390-1391.

［23］KEBUDI R，AMAYIRI N，ABEDALTHAGAFI M，et al. Position paper：challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings［J］. Pediatr Blood Cancer，2020，67（8）：e28309.

［24］FILBIN M，MONJE M. Developmental origins and emerging therapeutic opportunities for childhood cancer［J］. Nat Med，2019，25（3）：367-376. reWiPy/msShFRBVDlFBMXRupIAMHsuIZG8tQpvMIemy5BIAYpFxPS4qee+uxGgTl